N M van der Veen J F G M Brouns J P Doornbos W J van Wijngaarden
10.1007/s00404-010-1561-7
Arch Gynecol Obstet
2011 Jan;283(1):1-5.
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/20593191/
Abortifacient Agents, Nonsteroidal / adverse effects Abortion, Induced / adverse effects Misoprostol / adverse effects Ultrasonography, Prenatal Uterine Rupture / chemically induced Uterus / abnormalities Uterus / diagnostic imaging
Abortifacient Agents, Nonsteroidal / adverse effects Abortion, Induced / adverse effects Misoprostol / adverse effects Ultrasonography, Prenatal Uterine Rupture / chemically induced Uterus / abnormalities Uterus / diagnostic imaging Case Reports Review Abortifacient Agents, Nonsteroidal / administration & dosage Adult Female Humans Misoprostol / administration & dosage Pregnancy Pregnancy Trimester, First / drug effects Risk Treatment Outcome Uterine Rupture / diagnostic imaging Uterine Rupture / epidemiology Abortifacient Agents, Nonsteroidal Misoprostol
PMC3015193
20593191
Misoprostol and termination of pregnancy: is there a need for ultrasound screening in a general population to assess the risk for adverse outcome in cases of uterine anomaly?
2011